Biotech Management: The 5-Question Framework

The problem: You’ve found a biotech with a promising drug, clean Phase 2 data, and a large addressable market. The science checks out. But you can’t answer the central question: can this management team actually execute?

The solution: Run the management team through five questions. If they pass four, you have conviction. If they pass fewer than three, you’re betting on science without an operator , and in biotech, science without execution is a dead ticker.

Most biotech CEOs are brilliant scientists. That’s the problem. A scientist who discovers a drug is not the same person who navigates an FDA review, negotiates a licensing deal, or builds a commercial organization from zero. Here’s how to tell the difference.

Question 1: What’s Their Clinical Execution Track Record?

Forget the LinkedIn bio. Look at the drugs they’ve actually advanced.

How many drugs has this CEO (or CSO) taken from IND filing to FDA approval? If the answer is zero, you’re betting on a first-timer during the hardest stretch of drug development.

The Phase 2 to Phase 3 transition rate across biotech is roughly 30-45% (BIO industry analysis 2011-2020). That means two-thirds of drugs that looked good in Phase 2 fail in Phase 3. A management team that has never navigated a Phase 3 trial doesn’t know what it doesn’t know.

What to look for on the track record:

• IND-to-NDA experience: Has anyone on the leadership team filed and defended an NDA or BLA at the FDA? A CFO who’s done 12 IPOs matters less than a CMO (Chief Medical Officer) who’s done 1 FDA approval.
• Phase 2 to Phase 3 conversion: How many of their Phase 2 assets became Phase 3 assets? Compare to the industry ~33% baseline. Someone who’s 0-for-5 is not unlucky , they’re incapable of designing a registrational trial.
• Promotion from within: A CSO promoted to CEO who has never run a business is the single most common red flag in biotech. Science leadership and operational leadership are different skills.

Real example: Michael Severino, the new CEO of Sarepta (SRPT) as of July 2026, spent two decades at AbbVie and Amgen, where he helped bring drugs to market across immunology, oncology, and hepatitis C. He was hired specifically because Sarepta needed a turnaround operator, not a scientist , the board ran a comprehensive search and picked the person who had actually delivered drugs through the FDA, not someone who understood exon skipping.

Contrast that with a CSO-to-CEO promotion at a pre-revenue biotech where no one on the leadership team has ever filed an NDA. The first FDA interaction is the wrong time to learn how the FDA works.

Question 2: How Do They Handle Bad News?

Every biotech hits setbacks. The question is what management does next.

Pull up the press releases from the company’s last trial failure or CRL. Does the CEO:

• Call it straight? (“The primary endpoint was missed. We’re analyzing the data and will provide an update in 4-6 weeks.”)
• Or spin it? (“The trial demonstrated encouraging trends in a prespecified subgroup that warrant further investigation.”)

The spin is the tell. A CEO who spins a missed primary endpoint will spin a manufacturing delay, a clinical hold, and an FDA rejection. By the time you find out the real story, the stock is down 60%.

The three-spin test: Read the last three press releases where something went wrong. If all three lead with something positive that buries the bad news in paragraph six, management can’t be trusted.

Question 3: How Competent Is Their Capital Allocation?

A biotech CEO’s primary job is raising capital - at the right time, right price, right structure. Drug development is second.

Look at the dilution history:

• Did the company raise money before it needed it (cash runway >18 months) or after it was desperate (runway <6 months)? Companies that raise from a position of strength get better terms. Companies that wait until the last minute take whatever they’re offered.
• What’s the dilution per round? If a company raised $50M at a $200M pre-money valuation and then $75M at a $250M pre-money, each round diluted existing shareholders by ~20-23%. That’s normal. If a desperate raise came at a $40M pre-money for a $50M deal, existing shareholders got crushed.
• Is there an ATM facility and how aggressively is it used? Check shares outstanding quarter over quarter. A 2-3% increase per quarter is meaningful over two years.

Red flag: Frequent CFO changes. If a pre-revenue biotech has had three CFOs in four years, something is wrong with either the financial strategy or the board’s patience. Either way, you don’t want to be a shareholder when CFO #4 walks in.

Question 4: Does the CEO’s Stock Trading Match Their Public Statements?

SEC Form 4 filings tell you when insiders buy and sell. This is an underused tool in biotech investing.

A CEO buying $500,000 of stock in the open market is a stronger signal than any press release. A CEO selling 30% of their position the day after positive Phase 2 data is a stronger signal than any 8-K.

What to check:

• Buys: Are insiders buying on the open market during drawdowns? Cluster buying by multiple officers and directors during a sell-off is a positive signal in biotech.
• Sells: Are sales part of a pre-arranged 10b5-1 trading plan, or are they discretionary? Discretionary sales after good news are a red flag. The CEO knows more about the pipeline than you ever will.
• Post-catalyst sales: A CEO who sells on the pop after positive data is telling you the data wasn’t as good as the market thinks.

Question 5: Has Anyone on This Team Launched a Drug Commercially?

Pre-revenue biotech CEOs without commercial launch experience are betting that the hardest part of drug development ends at FDA approval. It doesn’t.

Building a sales force, negotiating payer contracts, setting a price that CMS won’t reject , these are skills that don’t exist in a preclinical or clinical-stage company. If the CEO has never been through a drug launch, and no one on the commercial team has either, you’re investing in a company that will learn commercial execution on your dime.

Vertex Pharmaceuticals (VRTX) is the model case: a management team that has launched multiple drugs across cystic fibrosis, with commercial infrastructure that scales. When Vertex acquires a new asset (like povetacicept for IgA nephropathy, with a PDUFA date of November 30, 2026), the market prices in execution premium because the track record justifies it.

At the other end of the spectrum: a pre-revenue biotech with one Phase 2 asset, a CEO who came from academia, and a commercial “strategy” that hasn’t been tested. The drug could work. The launch probably won’t.

Red Flags Checklist

Seven things that should make you pause before investing:

1. Frequent CFO changes (more than one in three years)
2. CEO selling stock after positive data (discretionary, not 10b5-1 planned)
3. CSO promoted to CEO with no business experience and no COO to compensate
4. History of missed timelines (three or more delayed trial readouts, delayed filings, or delayed launches)
5. Press releases that consistently bury bad news in paragraph six (apply the three-spin test)
6. No one on the leadership team has filed an NDA or BLA with the FDA
7. The CEO dodges direct questions on conference calls , if you hear “we’re excited about the data” three times in one Q&A without a specific answer, that’s not confidence, that’s evasion

The Real-World Test Case: Legend Biotech (LEGN)

In July 2026, Legend Biotech CEO Ying Huang abruptly resigned with no permanent successor named. The official statement said the departure “was not the result of any disagreement.” The same week, J&J reported jaw-dropping efficacy for its bispecific combination , Tecvayli plus Talvey slashed multiple myeloma progression risk by 89%.

A CEO leaving without explanation, while the company’s partner reports the best efficacy data in the space, is a management red flag regardless of what the press release says. Leadership instability at the top, during a period when Legend’s CAR-T franchise faces intense competition, means you factor execution risk into whatever Carvykti revenue model you’re running.

For the broader investing framework, see the guide to biotech investing.

The management team question isn’t a checkbox. It’s a valuation input. Bad management deserves a bigger discount rate, and that changes your entry price.

Company leadership data verified via SEC EDGAR filings, including Form 4 insider transactions and 10b5-1 trading plans.